FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2578843313> ?p ?o ?g. }

• W2578843313 abstract "Abstract Abstract 4070 Background: There are currently limited effective treatment options for patients (pts) with RRMM with prior exposure to lenalidomide (LEN), bortezomib (BORT) and chemotherapy. In a multicenter, randomized phase 2 study, POM with or without LoDEX (n=221) was active in RRMM pts who had received ≥2 prior therapies, including LEN and BORT (Richardson PG, et al. Blood 2011;118:abs 634); activity was also observed in those with disease refractory to LEN, BORT, or both (Vij R, et al. J Clin Oncol 2012;30:abs 8016). Here we characterize outcomes in the POM+LoDEX group (n=113) according to the prior treatment exposure. Methods: Pts with RRMM who had received ≥2 prior therapies, including LEN and BORT, and had progressive disease (PD) within 60 days of their last treatment were randomized (1:1 ratio) to POM+LoDEX (POM, 4 mg/day for days 1–21 of a 28-day cycle; LoDex, 40 mg/week) or POM alone. At randomization, pts were stratified by age, prior number of treatments, and prior thalidomide exposure. At progression, pts receiving POM alone could receive POM+LoDEX at investigator's discretion. All pts received thromboprophylaxis (daily low-dose aspirin). The endpoints in this study were progression-free survival (PFS), response rates (using European Bone Marrow Transplantation [EBMT] criteria), duration of response, time to response, overall survival (OS), and safety. Response data according to prior therapy were assessed by investigator assessment. Results: All 113 pts assigned to POM+LoDEX had prior exposure to LEN (100%), BORT (100%), and steroids (100%). Most pts had also received prior alkylator therapy (93%), stem cell transplant (SCT) (73%), and thalidomide (THAL) (68%); 49% had received prior anthracyclines. Regimens immediately prior to study entry included BORT (50%), LEN (39%), cyclophosphamide (13%), THAL (8%), vorinostat (8%), carfilzomib (5%), and melphalan (5%). The median number of exposures to LEN and BORT in prior lines was once (range 1–4) and twice (range 1–6), respectively. The majority of pts (80%) had received >3 prior therapies. The overall response rate (ORR) was 48% and 30% in pts who had received ≤3 and >3 prior therapies, respectively. Of the pts who had ≤3 vs > 3 prior therapies, 9% vs 1% pts achieved complete response (CR), 39% vs 29% pts achieved partial response (PR), 9% vs 12% pts achieved minimal response (MR) and 44% vs 36 % pts achieved stable disease (SD), respectively. ORR was 34% and appeared similar regardless of prior exposure to alkylators (33%), anthracyclines (35%), SCT (35%), or THAL (35%). Median duration of response was also similar in pts who had received prior alkylators (8.4 mos), anthracyclines (10.1 mos), SCT (7.7 mos), and THAL (7.7 mos). Of the 69 pts who had a best response of SD or PD to their last prior antimyeloma therapy, 21 pts (12 SD and 9 PD) achieved a PR and 3 pts (1 SD and 2 PD) achieved a CR with POM+LoDEX treatment. Responding pts had longer time to progression (TTP; 11.1 mos) with POM+LoDex compared with the TTP (4.4 mos) observed with their last antimyeloma regimen prior to study. The most common grade 3–4 adverse events in the POM+LoDEX group were neutropenia (41%), anemia (22%), pneumonia (22%), thrombocytopenia (19%), and fatigue (14%). The incidence of at least 1 grade 3–4 adverse event was 100% in pts with ≤ 3 prior therapies, and 88% in pts with >3 therapies. Conclusions: The combination of POM+LoDEX has demonstrated an ORR of 34% in heavily pretreated pts with RRMM who have been previously exposed to LEN, BORT, steroids, and other treatments. Early treatment of POM+LoDEX (≤3 prior therapies) achieved better ORR (48%) compared with pts who received POM+LoDex later (>3 prior therapies; ORR, 30%). Disclosures: Vij: Onyx: Consultancy, Research Funding; Millennium Pharma: Speakers Bureau; Celgene: Consultancy, Research Funding, Speakers Bureau. Off Label Use: Pomalidomide is an investigational drug and is not approved for the treatment of patients with any condition. Hofmeister:Celgene: Advisory Board Other, Honoraria. Richardson:Celgene, Millennium, Johnson & Johnson: Advisory Board Other. Jagannath:Onyx Pharma: Honoraria, Membership on an entity's Board of Directors or advisory committees; Merck Sharp & Dohme: Honoraria, Membership on an entity's Board of Directors or advisory committees; Millennium Pharma: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees. Siegel:Onyx: Advisory Board, Advisory Board Other, Honoraria, Speakers Bureau; Millennium Pharma: Advisory Board, Advisory Board Other, Honoraria, Speakers Bureau; Celgene: Advisory Board Other, Honoraria, Speakers Bureau; Merck: Advisory Board, Advisory Board Other, Honoraria, Speakers Bureau. Baz:Celgene, Millennium, Bristol Myers Squibb, Novartis: Research Funding. Chen:Celgene: Employment, Equity Ownership. Zaki:Celgene: Employment, Equity Ownership. Larkins:Celgene: Employment, Equity Ownership. Anderson:Acetylon, Oncopep: Scientific Founder, Scientific Founder Other; Celgene, Millennium, BMS, Onyx: Membership on an entity's Board of Directors or advisory committees." @default.
• W2578843313 created "2017-01-26" @default.
• W2578843313 creator A5012718640 @default.
• W2578843313 creator A5021230077 @default.
• W2578843313 creator A5023752321 @default.
• W2578843313 creator A5026151069 @default.
• W2578843313 creator A5028046297 @default.
• W2578843313 creator A5028521293 @default.
• W2578843313 creator A5032373476 @default.
• W2578843313 creator A5032464400 @default.
• W2578843313 creator A5043526996 @default.
• W2578843313 creator A5077110117 @default.
• W2578843313 date "2012-11-16" @default.
• W2578843313 modified "2023-09-30" @default.
• W2578843313 title "Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure" @default.
• W2578843313 doi "https://doi.org/10.1182/blood.v120.21.4070.4070" @default.
• W2578843313 hasPublicationYear "2012" @default.
• W2578843313 type Work @default.
• W2578843313 sameAs 2578843313 @default.
• W2578843313 citedByCount "1" @default.
• W2578843313 countsByYear W25788433132015 @default.
• W2578843313 crossrefType "journal-article" @default.
• W2578843313 hasAuthorship W2578843313A5012718640 @default.
• W2578843313 hasAuthorship W2578843313A5021230077 @default.
• W2578843313 hasAuthorship W2578843313A5023752321 @default.
• W2578843313 hasAuthorship W2578843313A5026151069 @default.
• W2578843313 hasAuthorship W2578843313A5028046297 @default.
• W2578843313 hasAuthorship W2578843313A5028521293 @default.
• W2578843313 hasAuthorship W2578843313A5032373476 @default.
• W2578843313 hasAuthorship W2578843313A5032464400 @default.
• W2578843313 hasAuthorship W2578843313A5043526996 @default.
• W2578843313 hasAuthorship W2578843313A5077110117 @default.
• W2578843313 hasConcept C126322002 @default.
• W2578843313 hasConcept C141071460 @default.
• W2578843313 hasConcept C2776063141 @default.
• W2578843313 hasConcept C2776364478 @default.
• W2578843313 hasConcept C2776694085 @default.
• W2578843313 hasConcept C2777063308 @default.
• W2578843313 hasConcept C2777478702 @default.
• W2578843313 hasConcept C2778524551 @default.
• W2578843313 hasConcept C2779609412 @default.
• W2578843313 hasConcept C2908647359 @default.
• W2578843313 hasConcept C71924100 @default.
• W2578843313 hasConcept C99454951 @default.
• W2578843313 hasConceptScore W2578843313C126322002 @default.
• W2578843313 hasConceptScore W2578843313C141071460 @default.
• W2578843313 hasConceptScore W2578843313C2776063141 @default.
• W2578843313 hasConceptScore W2578843313C2776364478 @default.
• W2578843313 hasConceptScore W2578843313C2776694085 @default.
• W2578843313 hasConceptScore W2578843313C2777063308 @default.
• W2578843313 hasConceptScore W2578843313C2777478702 @default.
• W2578843313 hasConceptScore W2578843313C2778524551 @default.
• W2578843313 hasConceptScore W2578843313C2779609412 @default.
• W2578843313 hasConceptScore W2578843313C2908647359 @default.
• W2578843313 hasConceptScore W2578843313C71924100 @default.
• W2578843313 hasConceptScore W2578843313C99454951 @default.
• W2578843313 hasLocation W25788433131 @default.
• W2578843313 hasOpenAccess W2578843313 @default.
• W2578843313 hasPrimaryLocation W25788433131 @default.
• W2578843313 hasRelatedWork W144049856 @default.
• W2578843313 hasRelatedWork W149907048 @default.
• W2578843313 hasRelatedWork W1942265032 @default.
• W2578843313 hasRelatedWork W1969662615 @default.
• W2578843313 hasRelatedWork W1972264308 @default.
• W2578843313 hasRelatedWork W1975916512 @default.
• W2578843313 hasRelatedWork W1983492903 @default.
• W2578843313 hasRelatedWork W1985147506 @default.
• W2578843313 hasRelatedWork W2013357246 @default.
• W2578843313 hasRelatedWork W2046118145 @default.
• W2578843313 hasRelatedWork W2059873406 @default.
• W2578843313 hasRelatedWork W2133986577 @default.
• W2578843313 hasRelatedWork W2142149038 @default.
• W2578843313 hasRelatedWork W2316160054 @default.
• W2578843313 hasRelatedWork W2555978778 @default.
• W2578843313 hasRelatedWork W2576557879 @default.
• W2578843313 hasRelatedWork W2782099884 @default.
• W2578843313 hasRelatedWork W173928540 @default.
• W2578843313 hasRelatedWork W1829454685 @default.
• W2578843313 hasRelatedWork W1847139499 @default.
• W2578843313 isParatext "false" @default.
• W2578843313 isRetracted "false" @default.
• W2578843313 magId "2578843313" @default.
• W2578843313 workType "article" @default.